The intersection of attention-deficit/hyperactivity disorder and substance abuse

Current Opinion in Psychiatry

Volumn 24, Issue 4, 2011, Pages 280-285

  Wilens, Timothy E ^a   Morrison, Nicholas R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

attention deficit hyperactivity disorder; prevention treatment; substance use disorder; treatment

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NICOTINE; PLACEBO;

ALCOHOLISM; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CIGARETTE SMOKING; COGNITIVE THERAPY; COMORBIDITY; CONDUCT DISORDER; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG MISUSE; HUMAN; LIVER DYSFUNCTION; PRESCRIPTION; RISK FACTOR; SUBSTANCE ABUSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; RISK FACTORS; SMOKING; SUBSTANCE-RELATED DISORDERS;

EID: 79958723406     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328345c956     Document Type: Article

References (36)

1. Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 2010; 122:97-109.
2. Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication - Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010; 49:980-989.
3. Frodl T. Comorbidity of ADHD and substance use disorder (SUD): a neuroimaging perspective. J Atten Disord 2010; 14:109-120.
4. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/ hyperactivity disorder and future substance use disorders: comparative metaanalyses. J Am Acad Child Adolesc Psychiatry 2011; 50:9-21.
5. Brook DW, Brook JS, Zhang C, Koppel J. Association between attentiondeficit/ hyperactivity disorder in adolescence and substance use disorders in adulthood. Arch Pediatr Adolesc Med 2010; 164:930-934.
6. Wilens T. Does ADHD predict substance use disorders? A 10-year follow-up studyofyoungadults withADHD. JAmAcadChildAdolescPsychiatry (in press).
7. Wilens T, Martelon M, Fried R, et al. Do executive function deficits predict later substance use disorders among adolescents and young adults? J Am Acad Child Adolesc Psychiatry (in press).
8. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165:597-603. (Pubitemid 351705336)
9. Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165:604-609. (Pubitemid 351705337)
10. Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 2008; 162:916-921.
11. Bejerot S, Ryden EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry 2010; 71:1590-1597.
12. Kollins SH, McClernon FJ, Van Voorhees EE. Monetary incentives promote smoking abstinence in adults with attention deficit hyperactivity disorder (ADHD). Exp Clin Psychopharmacol 2010; 18:221-228.
13. Willoughby MT, Kollins SH, McClernon FJ. Association between smoking and retrospectively reported attention-deficit/hyperactivity disorder symptoms in a large sample of new mothers. Nicotine Tob Res 2009; 11:313-322.
14. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk for psychoactive substance use disorder? Findings from a four year follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36:21-29. (Pubitemid 27024224)
15. Biederman J, Petty CR, Wilens TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008; 165:107-115. (Pubitemid 351704559)
16. Yule AM, Wilens TE, Martelon M, et al. Impact of exposure to parental substance use disorders (SUD) on SUD risk in girls and their siblings. New York, NY: American Academy of Child and Adolescent Psychiatry; 2010.
17. Barkley RA. ADHD in adults. Sudbury, MA: Jones and Bartlett Publishers; 2010.
18. Faraone SV, Biederman J, Spencer TJ, et al. Diagnosing adult attention deficit hyperactivity disorder: Are late onset and subthreshold diagnoses valid? Am J Psychiatry 2006; 163:1720-1729. (Pubitemid 44522480)
19. McAweeney M, Rogers NL, Huddleston C, et al. Symptom prevalence of ADHD in a community residential substance abuse treatment program. J Atten Disord 2010; 13:601-608.
20. Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010; 304:875-880.
21. Solanto MV, Marks DJ, Wasserstein J, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry 2010; 167:958-968.
22. Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010; 108:130-133.
23. Winhusen TM, Somoza EC, Brigham GS, et al. Impact of attention-deficit/ hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71:1680-1688.
24. Riggs P. Multisite of OROS-MPH for ADHD in substance abusing adolescents. In: Scientific proceedings of the 56th annual meeting for the American Academy of Child and Adolescent Psychiatry. Hawaii: AACAP; 2009.
25. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96:145-154.
26. Adler L, Wilens T, Zhang S, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict 2009; 18:393-401.
27. Adler L, Guida F, Irons S, Shaw D. Open label pilot study of atomoxetine in adults with ADHD and substance use disorder. J Dual Diagnosis 2010; 6:196-207.
28. Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry 2010; 49:573-582.
29. Wilens TE, Adler LA, Adamson J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:21-31.
30. Upadhyaya HP, Kroutil LA, Deas D, et al. Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population. Am J Addict 2010; 19:569-577.
31. Amelia AM, Garnier-Dykstra LM, Caldeira KM, et al. Persistent nonmedical use of prescription stimulants among college students: possible association with ADHD symptoms J Atten Disord 2010. [Epub ahead of print]
32. Janusis GM, Weyandt LL. An exploratory study of substance use and misuse among college students with and without ADHD and other disabilities. J Atten Disord 2010; 14:205-215.
33. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 2008; 12:115-125.
34. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006; 163:387-395. (Pubitemid 44469379)
35. Spencer TJ, Bonab AA, Dougherty DD, et al. A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. Int J Mol Med 2010; 25:261-265.
36. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009; 23:419-427.